✦ LIBER ✦

Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C

✍ Scribed by RG BATEY; A BENSOUSSAN; YANG YI FAN; S BOLLIPO; MA HOSSAIN

Book ID: 108949520
Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 96 KB
Volume: 13
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.1998.01550.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized double blind placebo-controll

Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C

✍ Lindsay Mollison; Leanne Totten; James Flexman; Miles Beaman; Robert Batey 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Chinese Herbal Medicine “Ba Wei Di Huang Wan” in the Treatment of Dementia

✍ Koh Iwasaki; Seiichi Kobayashi; Yuri Chimura; Mayumi Taguchi; Kazumi Inoue; Shig 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

A Double-Blind, Randomized, Placebo-Cont

A Double-Blind, Randomized, Placebo-Controlled Trial of Macrolide in the Treatment of Chronic Rhinosinusitis

✍ Ben Wallwork; William Coman; Alan Mackay-Sim; Lennart Greiff; Anders Cervin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Intrathecal Ziconotide in the Treatment

Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

✍ Mark S. Wallace; Steven G. Charapata; Robert Fisher; Michael Byas-Smith; Peter S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

A double-blind placebo-controlled random

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa

✍ I. Miller; C.D. Lynggaard; S. Lophaven; C. Zachariae; D.N. Dufour; G.B.E. Jemec 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr